XBiotech (XBIT) Return on Capital Employed (2015 - 2026)
XBiotech (XBIT) posted quarterly Return on Capital Employed of 36.32% for Q4 2025, down 1389.0% year-over-year from 2.82% in Q4 2024, and down 80.12% quarter-over-quarter from 20.16% in Q3 2025.
XBiotech (XBIT) Return on Capital Employed (2015 - 2026) Analysis & Trends
XBiotech's Return on Capital Employed history runs 11 years deep, the most recent figure standing at 36.32% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 1389.0% year-over-year to 36.32%; the TTM figure through Dec 2025 stood at 36.32% (down 1389.0% YoY), while the FY2025 annual figure was 33.41%, down 1194.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 36.32%, down from 20.16% in the prior quarter.
- The five-year high for Return on Capital Employed was 5.58% in Q1 2021, with the low at 36.32% in Q4 2025.
- The 5-year median for Return on Capital Employed is 15.63% (2023), against an average of 16.36%.
- The sharpest annual moves came in 2021 and 2025: Return on Capital Employed soared 140 bps in 2021, then plunged 1389 bps in 2025.
- XBiotech's Return on Capital Employed stood at 9.16% in 2021, then tumbled by 54 bps to 14.11% in 2022, then fell by 20 bps to 16.9% in 2023, then sank by 33 bps to 22.43% in 2024, then slumped by 62 bps to 36.32% in 2025.
- Business Quant data shows XBIT's Return on Capital Employed at 36.32% in Q4 2025, 20.16% in Q3 2025, and 20.71% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | -34.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.86% |
| Dec 31, 2025 | -36.32% |
| Sep 30, 2025 | -20.16% |
| Jun 30, 2025 | -20.71% |
| Mar 31, 2025 | -24.41% |
| Dec 31, 2024 | -22.43% |
| Sep 30, 2024 | -21.51% |
| Jun 30, 2024 | -20.98% |
| Mar 31, 2024 | -19.60% |
| Dec 31, 2023 | -16.90% |
| Sep 30, 2023 | -16.33% |
| Jun 30, 2023 | -14.93% |
| Mar 31, 2023 | -14.05% |
| Dec 31, 2022 | -14.11% |
| Sep 30, 2022 | -13.14% |
| Jun 30, 2022 | -11.85% |
| Mar 31, 2022 | -10.88% |
| Dec 31, 2021 | -9.16% |
| Sep 30, 2021 | -7.29% |
| Jun 30, 2021 | -6.77% |